Table 1

Baseline characteristics of the studies

Author	Year of publication	Year of study	Country	Design	Disease	N	Age (years)		Gender (male)	BCG
Author	Year of publication	Year of study	Country	Design	Disease	N	Mean	Median (range)	Gender (male)	BCG
Won	2017	2015	South Korea	Cohort	ATB	36	63.9	73 (15–86)	15	–
Won	2017	2015	South Korea	Cohort	LTBI	15	55.1	52 (36–75)	8	–
Wu	2017	2015	China	Cohort	ATB	25	51	22–85	18	17
Wu	2017	2015	China	Cohort	LTBI	36	48	7–76	12	31
Jeong	2015	2010	South Korea	RCT	ATB	33	–	30 (20–63)	19	21
Jeong	2015	2010	South Korea	RCT	LTBI	20	–	44 (22–60)	4	18
Clifford	2019	2012	Australia	RCT	ATB	38	–	28 (25–44)	19	22
Clifford	2019	2012	Australia	RCT	LTBI	43	–	26 (24–31)	21	33
Kim	2015	2010	South Korea	RCT	ATB	28	32.1	21–69	8	9
Kim	2015	2010	South Korea	RCT	LTBI	22	46.5	22–69	4	21
Wang	2018	2009	China	Cohort	ATB	28	46	26–55	16	17
Wang	2018	2009	China	Cohort	LTBI	34	43	15–62	15	25
Pathakumari	2015	2010	India	RCT	ATB	39	–	19–60	25	–
Pathakumari	2015	2010	India	RCT	LTBI	35	–	21–58	22	–
Hur	2016	2013	South Korea	RCT	ATB	52	43	26–60	29	–
Hur	2016	2013	South Korea	RCT	LTBI	31	45	38–52	20	–
Zhang	2017	2012	China	RCT	ATB	26	37	24–50	23	–
Zhang	2017	2012	China	RCT	LTBI	45	34	28–40	14	–
La Manna	2018	2013	Italia	RCT	ATB	27	–	17–82	21	–
La Manna	2018	2013	Italia	RCT	LTBI	32	–	17–84	24	–
You	2016	2012	South Korea	RCT	ATB	40	52.7	36.3–69.1	31	–
You	2016	2012	South Korea	RCT	LTBI	40	63.7	49.5–77.9	27	–
Suzukawa	2016	2010	Japan	RCT	ATB	31	37	21–48	18	–
Suzukawa	2016	2010	Japan	RCT	LTBI	29	42	23–55	12	–
Yao	2017	2016	China	Cohort	ATB	20	–	29 (16–67)	11	8
Yao	2017	2016	China	Cohort	LTBI	15	–	38 (20–67)	8	15
Wang	2012	2009	China	RCT	ATB	66	–	45 (16–86)	39	52
Wang	2012	2009	China	RCT	LTBI	73	–	41 (18–83)	35	54

ATB, active tuberculosis; BCG, Bacillus Calmette-Guerin; LTBI, latent tuberculosis infection; RCT, randomised controlled trial.